Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780858 | 1.00 | TSHR (0.54) | TSHRFAAHTRPV1HIF1AMAPT | |
| SCHEMBL21436162 | 1.00 | TSHR (0.54) | TSHRFAAHTRPV1HIF1AMAPT | |
| SCHEMBL28016022 | 1.00 | TSHR (0.54) | TSHRFAAHTRPV1HIF1AMAPT | |
| SCHEMBL19287165 | 1.00 | TSHR (0.54) | TSHRFAAHTRPV1HIF1AMAPT | |
| SCHEMBL8204966 | 1.00 | TSHR (0.54) | TSHRFAAHTRPV1HIF1AMAPT | |
| SCHEMBL4912351 | 0.98 | — | — | |
| SCHEMBL9007954 | 0.96 | TSHR (0.50) | TSHRFAAHTRPV1HIF1AMAPT | |
| SCHEMBL5255821 | 0.93 | — | — | |
| SCHEMBL29128731 | 0.90 | — | — | |
| SCHEMBL16568619 | 0.85 | TSHR (0.50) | TSHRFAAHTRPV1HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| CN-104918961-A | Improved peptide drugs for insulin resistance | MEDERIS DIABETES LLC | 2015-09-16 | — | — | CN | disclosed |
| US-9089515-B2 | Long chain N-alkyl compounds and oxa-derivatives thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1210082-B1 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | UNIV OXFORD (GB) | 2008-01-02 | — | — | EP | disclosed |
| EP-1210082-A2 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001010429-A2 | LONG CHAIN N-ALKYL COMPOUNDS AND OXA-DERIVATIVES THEREOF AND USE AS ANTIVIRAL COMPOSITIONS | THE CHANCELLOR, MASTERS, AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2001-02-15 | — | — | WO | disclosed |
| WO-1998042702-A1 | ENDOTHELIN-RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
| US-5792840-A | SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES | SANKYO COMPANY, LIMITED (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0437016-B1 | Lipid A analogues having immunoactivating and anti-tumour activity | SANKYO CO (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TSHR 4568/4885FAAH 4450/4885TRPV1 4623/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TSHR 4568/4885FAAH 4450/4885TRPV1 4623/4885 |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | TSHR 2541/4885FAAH 189/4885TRPV1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.